Neos Therapeutics

Neos Therapeutics develops, manufactures, and commercializes branded products using our proprietary, extended-release drug delivery technology platform. We have used this technology to develop products for the treatment of attention deficit hyperactivity disorder (ADHD), including an extended-release orally disintegrating tablet. We are also using this technology to develop two additional product candidates: Oral disintegrating tablets (ODT) Oral suspension dosage forms.
Type
Public
HQ
Grand Prairie, US
Founded
2008
Employees
81 (est)
Neos Therapeutics was founded in 2008 and is headquartered in Grand Prairie, US

Key People at Neos Therapeutics

Russ McMahen

Russ McMahen

Executive Vice President of Operations and Vice President of Scientific Affairs
Ellen Hoffing

Ellen Hoffing

Co-President & Chief Operating Officer
Vipin Garg

Vipin Garg

CEO
Dorothy Engelking

Dorothy Engelking

VP of Regulatory Affairs
Richard Eisenstadt

Richard Eisenstadt

CFO
Margaret Cabano

Margaret Cabano

VP of Operations

Neos Therapeutics Locations

Grand Prairie, US
Blue Bell, US

Neos Therapeutics Metrics

Neos Therapeutics Summary

Market capitalization

$109 M

Closing share price

$6.85
Neos Therapeutics's latest market capitalization is $109 M.

Neos Therapeutics Market Value History

Neos Therapeutics News

Neos Therapeutics Company Life

You may also be interested in